Medscape June 10, 2024
Bhanvi Satija And Sriparna Roy

(Reuters) – Evidence that weight-loss drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound can cut heart disease risk, treat sleep apnea and address other health issues may help convince more men to use them, five doctors who prescribe the medicines regularly told Reuters.

Men prefer to shed extra pounds with diet and exercise changes before reaching for drugs, if they address their weight at all, doctors and three healthcare industry analysts said in interviews.

Women are far less hesitant to seek a physician’s help with weight loss and management, they said.

The “typical weight management program is female predominant in our clinic. It’s almost two out of three patients are women, and that’s pretty much common across the country,”...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Patient / Consumer, Pharma / Biotech, Physician, Provider
New 'how-to guide' for future rapid vaccine development
Infographic: R&D Spending Growth of Top Pharma Companies
Medicare prescription drug pricing variance: 5 things to know
Payer group 'deeply concerned' by Medicare weight loss drug coverage proposal
Adoption Of Model-Informed Drug Development Can Improve Pharma ROI

Share This Article